The infectivity and host range of the ecotropic porcine endogenous retrovirus, PERV-C, is modulated by residues in the C-terminal region of its surface envelope protein  by Gemeniano, Malou et al.
lsevier.com/locate/yviroVirology 346 (200The infectivity and host range of the ecotropic porcine endogenous
retrovirus, PERV-C, is modulated by residues in the C-terminal
region of its surface envelope protein
Malou Gemeniano a, Onesmo Mpanju a, Daniel R. Salomon b,
Maribeth V. Eiden c, Carolyn A. Wilson a,*
a Laboratory of Immunology and Virology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, 8800 Rockville Pike,
HFM-725, Building 29B, Room 2NN12, Bethesda, MD 20892, USA
b Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
c Laboratory of Cellular and Molecular Regulation, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA
Received 29 July 2005; returned to author for revision 22 September 2005; accepted 18 October 2005
Available online 23 November 2005Abstract
Endogenous retroviral genetic material serves as a reservoir for the generation of retroviral pathogens by recombination between activated
endogenous or exogenous infectious agents. Some porcine tissues actively express infectious porcine endogenous retroviruses (PERVs). Of the
three classes of PERV characterized to date, two, PERV-A and B, are capable of infecting human cells in vitro, whereas PERV-C cannot. Here, we
demonstrate that the PERV-C envelope surface protein (SU) when disassociated from its C-terminus binds human cells. Further, we show that
PERV-C binding to human cells is not inhibited in 293 cells productively infected with PERV-A, confirming that the molecule PERV-C interacts
with on human cells is distinct from that used by PERV-A. Moreover, we demonstrate that the envelope region encompassing the proline-rich
region is required for binding to cells in addition to the putative variable region A (VRA) and B (VRB). The region in the C-terminus of the SU
that alters the binding and infectivity properties of PERV-C differs by only nine residues from the analogous region of PERV-A. Caution may be
warranted even when a xenotransplantation product is from source pigs that do not express human-tropic viruses, as minimal mutations within
PERV-C combined with selection in a human recipient could render PERV-C infectious in humans.
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domesticated pigs and their wild relatives in the Families
Suidae and Tayassuidae (Niebert and Tonjes, 2005; Patience et
al., 2001). Detailed studies of the LTR structure among these
porcine relatives indicate a relatively recent introduction of the
porcine endogenous retrovirus (PERV) sequences into the
germline, dating to approximately 7.6  106 years ago (Tonjes
and Niebert, 2003). Presumably because these are relatively
recent additions to the porcine germline, at least some loci
present in the pig genome are still encoding infectious
retroviruses of the gammaretrovirus genus, but not of other
retroviral genera (Patience et al., 2001). The observation that
porcine cells express infectious gammaretroviruses poses a0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.10.021
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E-mail address: wilsonc@cber.fda.gov (C.A. Wilson).safety concern when considering using pigs as source animals
for human cell, tissue, and ultimately, organ transplantation. In
that context, careful analysis of the viral determinants for
human cell tropism is critical.
There are three receptor classes of PERV, named A, B, and
C, identified by a combination of sequence divergence, in vitro
host range analysis, and classical interference studies (Akiyoshi
et al., 1998; Le Tissier et al., 1997; Takeuchi et al., 1998). The
isolation of two homologous cDNAs that encode functional
receptors for PERV-A, neither of which was functional for
PERV-B or PERV-C, confirmed the distinct receptor specificity
of these viruses (Ericsson et al., 2003). Of the three receptor
classes, only PERV-A and PERV-B are infectious for human
cells in vitro. Viruses of the PERV-C class have an ecotropic
host range; they are only capable of infecting porcine cells
(Takeuchi et al., 1998). However, it has been reported by two6) 108 – 117
www.e
Fig. 1. Schematic representation of PERV-A and PERV-C SU-rIgG fusion
proteins. The putative functional domains, VRA, VRB, and PPR, of PERV Env
are indicated by shaded, stipled, and hatched boxes, respectively. All proteins
shown are fusion proteins of various regions of PERVand the coding sequences
for residues 96–323 of the rabbit immunoglobin gamma heavy-chain gene,
constructed as described in the Materials and methods.
M. Gemeniano et al. / Virology 346 (2006) 108–117 109independent laboratories that during in vitro stimulation and
culture of primary porcine peripheral blood mononuclear cells
derived from NIH mini-swine, viruses with envelope sequences
that appear to be derived by recombination between PERV-A
and PERV-C may arise that are infectious for human cells
(Wilson et al., 2000; Oldmixon et al., 2002). Subsequent
analysis suggested that the recombination may occur during the
in vitro culture, since sequences bearing these recombinant
envelopes could not be found in the genome (Scobie et al.,
2004; Wood et al., 2004). In addition, an isolate of human-
tropic PERV with a recombinant A/C envelope, PERV-14/220,
has been shown to have higher titers on human cells than the
‘‘prototype’’ PERV-A (Harrison et al., 2004). The genetic
determinants of the increased infectivity titers of the recombi-
nant envelope were identified in two domains: a single amino
acid residue at position 140, and the proline-rich region (PRR)
(Harrison et al., 2004).
To date, only limited experimental data exist to identify the
genetic determinants of human tropism for PERV. A receptor-
binding domain (RBD) for PERV has been inferred to consist
of regions analogous to the RBDs identified in homologous
gammaretroviruses, such as the murine leukemia viruses
(MLVs). The RBD for MLVs has been shown to require the
N-terminal 120–200 amino acid sequences of the envelope,
depending on the receptor class (reviewed in Overbaugh et al.,
2001). The specific structural domains within the RBD that
have been shown to be critical for receptor specificity through
studies with chimeric envelopes and site-directed mutagenesis
have been designated variable regions A and B (VRA and
VRB). Interestingly, a third region that shows some variability,
the proline-rich region (PRR), is not important for receptor
binding for most MLVs, although it is a critical determinant for
structural stability and for facilitating the later stages of virus
entry (LaVillette et al., 2000; Wu et al., 1998).
No studies of the regions of PERV-C envelope protein
required for receptor binding have been performed. Herein, we
report the development of reagents and methods for measuring
specific binding of soluble PERV-A and PERV-C envelope
glycoproteins and results obtained using this assay to identify
the regions of the PERV-A and PERV-C envelope that
participate in receptor binding. Further, we employed retroviral
vectors bearing PERV-A/PERV-C chimeric envelopes and
similarly constructed chimeric surface (SU) envelope to
examine regions that are critical for human cell tropism by
measuring both binding and infection. In these studies, we have
identified a region of the PERV-C SU that confers the ability to
bind and infect human cells. Finally, we show here that 100
residues at the C-terminus of the PERV-C SU reduce both
binding and infection of human cells.
Results and discussion
Construction of soluble epitope tagged PERV-A and PERV-C
SU proteins
Based on homology to murine leukemia viruses, regions of
the PERVenvelope have been identified as putative VRA, VRB,and PRR domains (Le Tissier et al., 1997) (these regions are
represented schematically in Fig. 1). We used cDNAs encoding
various lengths of PERV-A and PERV-C SUs fused in-frame
with the rabbit immunoglobulin G heavy chain (SU-rIgG).
PERV-A 200 and PERV-C 200 retain the N-terminal 200
residues of the PERV-A or PERV-C SU, respectively. These
N-terminal residues contain the putative VRA and VRB
domains, but exclude the PRR. PERV-A 360 and PERV-C 360
retain the N-terminal 360 amino acids of each SU, including
VRA, VRB, and PRR domains. PERV-A 460 and PERV-C 440
correspond to the full-length SU. We also constructed two
hybrid SU-rIgG proteins, PERV-A/C and PERV-C/A. PERV-A/
C contains the N-terminal 333 amino acids of PERV-A,
encoding VRA, VRB, and PRR, fused in-frame to the C-
terminus of the PERV-C SU. PERV-C/A contains the N-terminal
312 amino acids of PERV-C SU fused in frame to the C-terminus
of the PERV-A SU. As a control, we used an SU-rIgG fusion
protein derived from the avian leukosis virus (ALV) (Zingler
and Young, 1996). Each expression plasmid was transiently
transfected into 293Tcells and supernatant containing the fusion
proteins was harvested 72 h post-transfection, as described in
Materials and methods. Immunoblot analysis using the anti-
rabbit IgG antibody reacted with the harvested materials
demonstrated that all of the fusion proteins were of the
appropriate size (Fig. 2). An anti-rabbit IgG ELISA assay was
used to standardize the amount of protein used in subsequent
assays, as described in Materials and methods.
PERV-A and PERV-C 360 efficiently bind porcine cells
To validate the utility of PERV-A and PERV-C 360 SU-IgGs
as functional PERVenvelope ligands, we examined the binding
characteristics of both PERV-A 360 and PERV-C 360 on a
porcine cell line, ST-IOWA using a FACS-based binding assay
Fig. 3. Binding properties of PERV-A and PERV-C SU-rIgG on porcine ST
IOWA cells. ST-IOWA cells were exposed to increasing concentrations o
PERV-A 360 (black bars), PERV-C 360 (grey bars), or ALV (stipled bars) and
then incubated for 30 min on ice with anti-rabbit IgG antibody conjugated to
fluorescein isothiocyanate. To determine PERV SU-rIgG binding, fluorescence
intensity was measured by analyzing 10,000–15,000 live cell events on
FACScan apparatus. The y-axis represents the relative mean fluoresence
intensity (MFI) with the highest mean fluorescence corresponding to a value o
one. Results shown are representative of three or more experiments. Al
experiments were done in triplicate.
Fig. 2. Western blot analysis of PERV SU-rIg fusion proteins. 293T cells were
transfected with either PERV-A 200, PERV-C 200, PERV-A 360, PERV-C 360,
PERV-A 460, PERV-C 440, PERV-A/C, or PERV-C/A rabbit IgG heavy chain
tagged plasmids. Seventy-two hours post-transfection, cell culture supernatants
were immunoprecipitated using 20% protein A-sepharose beads and proteins
were electrophoretically separated on SDS-12% polyacrylamide gel. Immuno-
blot analysis was performed using an anti-rabbit IgG antibody, as described in
Materials and methods.
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both PERV-A and PERV-C infection and therefore express
receptors for both of these viruses (Takeuchi et al., 1998; Wilson
et al., 2000). As shown in Fig. 3, the relative mean fluorescence
intensity (MFI) associated with binding on ST-IOWA cells
incubated with either PERV-A 360 or PERV-C 360 increased
with increasing concentrations of each SU-IgG. In contrast, the
control ALV SU-IgG did not show a shift in MFI, even at the
highest doses tested. Therefore, as anticipated from previous
studies showing that ST-IOWA cells are susceptible to both
PERV-A and PERV-C, we have now clearly demonstrated that
these cells also bind to both PERV-A and PERV-C envelope
ligands comprising the first 360 residues of their respective
envelope SU proteins.
PERV-A-360 binds specifically to rabbit cells expressing the
human PERV-A receptor
To determine the binding characteristics of soluble PERV-A
360 and PERV-C 360 on cells expressing the human PERV-A
receptor (hPAR-2), we compared the ability of PERV-A and C
SU-rIgG proteins to bind rabbit SIRC cells (cells that lack
receptors for PERV-A and PERV-C) or SIRC/PAR cells (cells
that express the human PERV-A receptor). As shown in Fig. 4,
binding of PERV-A 360 and PERV-C 360 was not observed on
SIRC cells, whereas a marked shift in MFI was observed when
PERV-A 360 was incubated with SIRC/PAR cells. In contrast,
no shift in fluorescence was observed following FACS-based
binding analysis of PERV-C 360 SU-rIgG on either SIRC or
SIRC/PAR cells, despite increasing concentrations of soluble
SU (Fig. 4). In contrast, for PERV-A 360, a dose-responsive
increase in MFI was observed with increasing doses of PERV-
A 360. Together, these results demonstrate that PERV-A 360
binding is specific to SIRC cells expressing the human PERV-
A receptor. The finding that PERV-C 360 does not bind cells
expressing hPAR-2 confirms previous findings that hPAR-2
does not function as a PERV-C receptor (Ericsson et al., 2003).
Ligands comprising solely the VRA and VRB region of PERV-A
fail to bind cells expressing the PERV-A receptor
Having demonstrated that both the PERV-A 360 and PERV-
C 360 SU proteins bind to porcine cells and that PERV-A 360
binds to cells expressing the PERV-A receptor, we next wenton to assess more precisely the region(s) of the PERV SU
protein that account for their respective receptor specificity. We
tested a panel of SU-rIgG fusion proteins (shown in Fig. 1) for
their ability to bind SIRC/PAR cells. As expected from the
results with PERV-C 360, none of the PERV-C-derived SU-
rIgG fusion proteins bound either SIRC or SIRC/PAR cells
(Fig. 5A). In contrast, PERV-A 360 and PERV-A 460 were able
to bind specifically to SIRC/PAR cells, but not control SIRC
cells. PERV-A 200 was unable to bind SIRC/PAR cells. These
results demonstrate that the N-terminal 200 amino acids,
spanning both the VRA and VRB regions of the PERV-A SU
are not sufficient to allow binding to cells expressing a
functional human receptor for PERV-A and support previous
findings that the entire SU region of PERV-A was required for
PERV-A to bind its receptor (Watanabe et al., 2005). However,
Watanabe et al. did not analyze the receptor binding ability of
PERV envelopes where the envelope ligand contained residues
that include the PRR yet did not extend to the carboxy terminus
of SU, making it difficult to interpret whether the PRR was the
sole determinant in the C-terminus of SU required in addition
to RBD for PERV-A to bind its receptor. Our analysis of the
binding characteristics of PERV-A 360 versus PERV-A 460
SU-IgG fusion proteins allows us to define more specifically
the region in the C-terminus of the PERV-A SU that is required,
for receptor binding—namely, the PRR.
Our results provide the first demonstration of a specific
requirement for the160 amino acid region including the PRR
segment in addition to ‘‘RBD’’, classically defined as com-
prising the VR-A and VR-B regions, but not the PRR, to
facilitate receptor binding by a gammaretroviral envelope
ligand. Other studies have implicated the PRR as playing a
role in murine leukemia virus (MLV) post-binding fusion
events (Lavillette et al., 2001, 2002). The PRR is also thought
to be an integral component contributing to MLV particle
stability (Lavillette et al., 2002; Wu et al., 1998) and the
C-terminal region of feline leukemia virus subgroup B (FeLV-
B) SU has been demonstrated to play a role in post-binding
entry of FeLV-B into cells expressing PiT receptors (Sugai et-
f
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Fig. 4. Binding properties of PERV-A and PERV-C SU-rIgG on SIRC and SIRC/PAR SIRC (white bars) and SIRC/PAR (black bars) were incubated with increasing
concentration of PERV-A 360 and PERV-C 360 proteins, with MFI determined as described in Fig. 3, with the exception that the data shown are representative of
single observations of each data point shown.
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al., 2002), regions outside of the classic RBD have not been
shown to play a role in expanding receptor utilization
properties. Faix et al. (2002) used chimeric FeLV-A/FeLV-B
envelope proteins to show that regions C-terminal to the FeLV-
B RBD were required for binding certain orthologs of the
FeLV-B receptor, PiT1. However, the specific contribution of
the PRR region of FeLV-B in virus binding was not examined.
Identification of regions within the PERV-A and PERV-C SU
that confer receptor specificity
To assess the regions within PERV-C SU that are required
for receptor binding, we examined the ability of the same panel
of SU-IgGs to bind porcine ST-IOWA cells (Fig. 5B).
Interestingly, neither soluble PERV-A 200 nor PERV-C 200
SU ligands were able to bind ST-IOWA porcine cells whereas
both PERV-A 360 and PERV-C 360 efficiently bound to theseFig. 5. Binding properties of PERV SU-rIgG fusion proteins on SIRC, SIRC/
PAR (a) and ST-IOWA (b). (A) SIRC (hatched bars) or SIRC/PAR (black bars)
(B) ST-IOWA cells were incubated with 500 ng/ml of each indicated SU-rIgG
fusion protein with MFI determined as described in Fig. 3.cells. Thus, similar to the results obtained using PERV-A on
SIRC/PAR, we found that both PERV-A and PERV-C require
the 160 amino acid region including the PRR for efficient
receptor binding.
Regions in the C-terminus of PERV-C SU inhibit binding and
infection of human cells
PERV-A but not PERV-C infects human cells such as
human embryonic kidney 293 cells (Takeuchi et al., 1998). In
order to localize specifically the regions within PERV-A that
are important for its human tropism, we assessed binding of
PERV-A/C-IgG fusion proteins containing the N-terminal 333
amino acids to various cell types (Fig. 1). As expected, the
PERV-A/C SU-IgG was able to bind SIRC/PAR cells (Fig.
5A). It is interesting to note that this ligand composed of the
N-terminal 333 residues of PERV-A and residues 334–440 of
PERV-C bound both SIRC/PAR and human 293 cells
significantly less efficiently then did the PERV-A 360 or
PERV-A 460 ligands (P* < 0.05) (Figs. 5A and 6A), while
there was no significant difference among the binding of
these three ligands to ST-IOWA cells (Fig. 5B). These
combined observations suggest that there may be sequences
in the C-terminal region of the PERV-C SU that inhibit
binding to human cells, without effecting binding to porcine
cells.
To test this hypothesis, we compared the binding efficiency
of PERV-C 360 to PERV-C 440. Similar to PERV-A binding,
we found no statistical difference in the MFI measured for
PERV-C 360 compared to PERV-C 440 on ST-IOWA cells
(Fig. 5B). However, when we examined the relative binding
efficiency on human 293 cells, the MFI of PERV-C 440 was
significantly reduced compared to PERV-C 360 (P < 0.05)
(Fig. 6B), further reinforcing the observation that the C-
terminal 100 amino acids inhibits PERV-C SU binding to
human cells. The unanticipated finding that PERV-C 360 binds
human 293 cells prompted us to rule out non-specific binding
of PERV-C 360 to 293 cells. Therefore, we assessed the
binding of PERV-C 360, over a range of concentrations and
found that the shift in relative MFI corresponded to increasing
concentrations of PERV-C 360 (Fig. 6C). These data are
suggestive that PERV-C 360 binding to human cells is specific.
Similar to our analysis on ST-IOWA cells (Fig. 5B), PERV-C
200 showed only a slight increase in mean fluorescence above
Fig. 6. Binding properties of PERV-SU-rIgG on human 293 cells. (A) Human 293 cells were incubated with 500 ng/ml of PERV-A SU-rIgG. (B) Human 293 cells
were incubated with 500 ng/ml of PERV-C SU-rIgG. (C) Human 293 cells were exposed to increasing concentration of PERV-A or PERV-C 360. Unstained cells,
cells incubated with anti-rabbit IgG antibody conjugated to FITC only, or cells incubated with ALV SU-rIgG were used as negative controls. Cells were incubated for
30 min on ice with anti-rabbit IgG antibody conjugated to fluorescein isothiocyanate with MFI determined as described in Fig. 3. The y-axis represents the average
plus the standard error of the relative mean fluoresence intensity with the highest mean fluorescence corresponding to a value of one. All experiments were
performed in triplicate.
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suggesting again the requirement for the region including the
PRR to facilitate receptor binding.
The C-terminus of PERV-A SU confers human cell binding and
infectivity on PERV-C SU
The finding that binding of PERV-C 440 to human cells is
lower than that observed for PERV-C 360 suggests that there
are sequences in the C-terminus of PERV-C SU that inhibit SU
binding. In order to test whether this may account for why 293
cells are resistant to PERV-C, we assessed the ability of
retroviral vectors bearing a PERV-C/A chimeric envelope to
bind and infect human 293 cells. As shown in Fig. 6B, PERV-
C/A was able to bind human 293 cells to an extent similar to
that obtained with PERV-C 360, and the shift in MFI was
statistically greater than that for the PERV-C 440 ligand (P <0.05). However, PERV-C/A was not able to bind SIRC/PAR
cells (Fig. 5A), indicating that the binding of PERV-C/A to
human cells requires a molecule distinct from the PERV-A
receptor.
To examine whether the effect of the C-terminus on binding
also influences infectivity, we used a retroviral vector pseudo-
type composed of MoMLV core proteins and a vector genome
encoding beta-galactosidase surrounded by various PERV
envelopes. As shown in Fig. 7, all vectors showed comparable
titers on ST-IOWA cells; however, vectors bearing a PERV-C
envelope were unable to infect SIRC/PAR cells or 293 cells. In
contrast, vectors with the PERV-C/A envelope were able to
infect 293 cells, albeit at a very low titer. Interestingly, these
same vectors were not able to infect SIRC/PAR cells, suggesting
that hPAR-2 does not function as a receptor for these vectors.
Vectors bearing the PERV-A envelope were able to infect all
three cell lines, SIRC/PAR, ST-IOWA, or human 293 cells.
Fig. 8. Effect of virus infection on PERV SU-rIgG binding. (A) 293 cells
chronically infected with PERV-A virus, strain 14/420 (293/14220, shown as
black bars) as well as uninfected 293 cells (grey bars) or (B) ST-IOWA
productively infected with PERV-C or uninfected ST-IOWA cells were
incubated with 500 ng/ml of the indicated SU-IgG or GALV-RBD with MFI
determined as described in Fig. 3. The y-axis represents the percent binding
using the mean value fluoresence intensity of PERV-A 360 binding to 293 cells
as 100%. Unstained cells, cells incubated with anti-rabbit IgG conjugated to
FITC only, or cells incubated with ALV SU-rIgG were used as negative
controls, and GALV-RBD was used as a positive control.
Fig. 7. Infectivity properties of viral vector pseudotypes bearing PERV-A,
PERV-C, PERV-A/C, or PERV- C/A envelopes. The infectivity of the indicated
viral vectors on SIRC/PAR, ST-IOWA, and 293 cells was determined by
histochemical stain of target cell 72 h after exposure to each viral vector, as
described in Materials and methods. All infections were performed in triplicate,
and results shown are blue-forming units per ml of virus-containing
supernatant.
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analogous manner to the PERV-C/A SU with the addition of
PERV-C-derived sequences in the TM, showed a 100-fold
decrease in infectivity titer on human 293 cells compared to
PERV-A vectors. These results correspond to the observation
that the PERV-A/C SU had decreased binding on human 293
cells, and offers supportive evidence that regions in the
C-terminus of the SU of PERV-C negatively impact infection
of human cells as well as binding.
PERV-C binds a receptor present on human cells that is
distinct from the PERV-A receptor
To test whether PERV-C 360 binding to 293 cells can be
blocked after infection with PERV-A, we analyzed the relative
MFI of PERV-A 360 and PERV-C 360 on 293 cells
productively infected with PERV-14/220 (a virus with a
PERV-A envelope receptor specificity) (Harrison et al., 2004)
compared to uninfected 293 control cells. As expected, PERV-
14/220 infected 293 cells exhibited a 60% reduction of PERV-
A 360 binding compared to uninfected 293 (Fig. 8A). In
contrast, no difference in the level of binding by PERV-C 360
was observed with either infected or uninfected cells. As a
control for non-specific effects from 14/220 infection, an SU
from Gibbon ape leukemia virus (GALV-RBD) was used. The
level of binding observed with GALV-RBD, like PERV-C 360,
was similar in either uninfected or infected 293 cells. As a
control, we also performed the inverse experiment to compare
the relative binding efficiency on uninfected ST-IOWA cells
compared to ST-IOWA cells infected with PERV-C. As
expected, the PERV-C infected cells inhibited PERV-C 360
binding by over 80% (Fig. 8B), while infection with PERV-C
had no effect on the binding of PERV-A 360 or GALV-RBD
controls.
Together, these data demonstrate that the binding and
infectivity of PERV-C 360 or PERV-C/A enveloped vectors,
are mediated by a receptor that is distinct from that of thePERV-A receptor present on human cells. We have shown
that the C-terminal 100 amino acids are critical in modulating
the binding and infectivity properties of the PERV-C
envelope. There are only 9 amino acid residues which differ
between PERV-A and PERV-C in this region (Fig. 9),
suggesting that relatively minor genetic alterations of a
PERV-C genome may confer human tropism on a naturally
occurring PERV-C isolate. The observation that the genetic
loci encoding PERV are naturally undergoing recombination
events, at least when activated ex vivo (Scobie et al., 2004),
will presumably lead to increased genetic diversity of PERV
isolates. While it has been proposed that the use of PERV-A
and PERV-B free source animals would reduce the risk of
PERV transmission to a human recipient of a porcine
xenotransplantation product, our results combined with the
contribution of ongoing recombination among PERV-C
encoding loci suggest that with minimal genetic changes to
PERV-C a human-tropic variant of PERV-C may be selected
after human xenotransplantation.
It remains to be determined whether the nine residues
altered in the C-terminus of PERV-C expand its receptor
Fig. 9. Amino acid differences in the C-terminal region of the PERV-A and PERV-C SU. Schematically shown are the PERVenvelope domains that are important for
receptor binding (the putative functional domains, VRA, VRB, and PPR, of PERV SU are indicated by shaded, stipled, and hatched boxes, respectively). The boxed
region indicates the amino acids that distinguish PERV-A and PERV-C (PERV-A envelope amino acids 342–460). Identical amino acids are shown as dots when not
to scale, or as dashes, when individual amino acids are represented.
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surface receptor protein or by allowing this virus to employ the
human ortholog of the porcine PERV-C receptor. Precedents
exist for both. For example FeLV-B, a recombinant retrovirus
resulting from recombination of FeLV-A, a feline ecotropic
virus, with endogenous sequences within the cat genome, has a
broad in vitro host range which includes human cells as well as
a wide variety of cells derived from different animal species.
FeLV-B utilizes a cell surface receptor, PiT1 that is distinct
from the FeLV-A receptor for infection of target cells (Takeuchi
et al., 1992). The 10A1 strain of MuLV provides a second
example of a gammaretrovirus that arose as a consequence of
recombination between the exogenous 4070A MuLV and
endogenous retroviral elements and has an expanded host
range. The expanded host range of 10A1 results from the
ability to use a novel receptor in addition to the 4070A
receptor. As few as six residues in the VRA and VRB differ
between the 10A1 and 4070A envelopes, and these differences
have been demonstrated to account for the expanded host range
of 10A1 (Han et al., 1997). To exemplify the second
possibility, i.e., that of a recombinant virus utilizing an
expanded repertoire of orthologous receptors, it has also been
shown that different FeLV-B isolates can employ different PiT1
orthologs for entry: only some FeLV-B recombinants can infect
Rat NRK cells and mink cells for example (Faix et al., 2002).
PERV PRR has been previously implicated in enhancing the
titers of PERV-A/C recombinant viruses (Harrison et al., 2004).
Recently, a study to identify the RBD for PERV-A showed that
full-length PERV-A SU was required for receptor binding.
VRA and VRB were not sufficient to confer PERV-A receptor
binding. In contrast, chimeric PERV envelope protein contain-
ing PERV-B derived VRA and VRB, but not PRR, was
sufficient for PERV-B to bind cells (Watanabe et al., 2005).
This report is the first to show that the region including the
PRR of PERV-A and PERV-C plays an important role in
receptor binding and infection of human cells and that the
receptor binding determinants for PERV-C differ from those of
PERV-B.
Materials and methods
Cells
Human embryonic kidney 293 (ATCC 1573), 293T
(obtained from Cell Genesys, Foster City, CA), and porcineST-IOWA (obtained from R. Fister, Tufts University, Boston,
MA) cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Biosource International, Camarillo, CA)
supplemented with 10% fetal bovine serum (FBS), 2 mM
glutamine, penicillin (100 U/ml), and streptomycin (100 U/ml).
SIRC cells (rabbit corneal fibroblasts, ATCC CCL-60) and
SIRC/PAR, SIRC cells stably expressing human PERV-A
receptor-2 cDNA (hPAR-2) (Ericsson et al., 2003), were kindly
provided by Dr. Clive Patience (Boston, MA) and were grown
in Eagle’s minimal essential medium (EMEM) (Biosource
International, Camarillo, CA) supplemented with 10% FBS, 2
mM glutamine, 1 mM sodium pyruvate, penicillin (100 U/ml),
and streptomycin (100 U/ml). 293 cells productively infected
with PERV-A strain 14/220 were also a kind gift of Dr. Clive
Patience. The ST-IOWA cells productively infected with
PERV-C were described previously (Takefman et al., 2001).
All cells were incubated at 37 -C with 5% CO2.
Derivation of PERV env expression plasmids
PERV-A sequences were derived from a PERV-NIH
envelope cDNA originally obtained from activated PBMC
from NIH minipigs (Wilson et al., 2000) and introduced into a
mammalian expression vector by amplification of PERV-NIH
env cDNA using PCR with the following primers: 5V primer
Penv3-SalKoz (5VGTACGTCGACGGAATCTC CACC
TGCCACCATGCATCCCACG3V) and 3V primer PERVenv4-
NotI (5VGTGTGTGCGGCCGCCCTTTCATTCCCCACTTC
TTGTC3V). Penv3-SalKoz introduces a Kozak consensus
sequence for optimized eukaryotic translation initiation
(Kozak, 1985). The amplified fragment was digested with SalI
and NotI, and ligated into pC1neo (Invitrogen, Carlsbad, CA).
Sequence analysis was performed using Big Dye Chemistry on
an ABI 310 genetic analyzer (PE Biosystems, Foster City, CA).
PERV-C env cDNAwas obtained by reverse transcription of
RNA isolated from ST-IOWA cells exposed to NIH mini pig
plasma as previously described (Takefman et al., 2001). The
PERV-C env cDNAwas amplified by PCR using the following
primers: 5V primer, PERVenvOM2 (5VGAGGCCTA CTCAG-
GAGGAGGAGACT3V) and 3V primer, PERVenv4-NotI and
subcloned into pCR2.1 (Invitrogen, Carlsbad, CA). Identity was
confirmed by sequence analysis and compared to previously
published PERV-C env sequences (Akiyoshi et al., 1998).
PERV-C env was then amplified by PCR using the Penv3-
SalKoz and PERVenv4not1, which allowed the incorporation of
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subcloning into pC1neo at the SalI–NotI sites, as described
above. The plasmids encoding the entire PERV-A env and
PERV-C env are referred to as pC1neoPERVA-1.38.2 and
pC1neoPERVC-3.7.2, respectively, throughout the remaining
text.
Two chimeric envelope cDNAs were constructed by
substitution of a 1000 bp ApaI and SalI fragment from
pC1neoPERVC-3.7.2 into pC1neoPERVA-1.38.2 to obtain
pC1neoPERVA/C. The resulting pC1neoPERVA/C encode
residues 1–333 of PERV-A SU fused in frame to the C-term
334–640 residues of PERV-C envelope. The analogous C/A
construct was created similarly by substituting a 1000 bp ApaI
and SalI fragment from pC1neoPERVA-1.38.2 into pC1neo-
PERVC-3.7.2 to obtain pC1neoPERVC/A. pC1neoPERVC/A
contains residues 1–312 of PERV-C SU in frame with the
residues 312–660 of PERV-A SU/TM.
Derivation of plasmids encoding PERV SU-rabbit
immunoglobin (PERV SU-rIgG) fusion proteins
The PERV SU-rIgG fusion proteins PERV-A 360, PERV-C
360, PERV-A 460, PERV-C 440, PERV-A/C, and PERV-C/A
SU-rIgG were constructed using pC1neoPERVA-1.38.2 and
pC1neoPERVC-3.7.2 plasmids as templates. PERV-A 360 and
PERV-C 360 were made by ligating three DNA fragments: (1)
a 5461 bp NotI–BamH1 fragment of pC1neoPERVA-1.38.2 or
pC1neoPERVC-3.7.2, which contains the coding sequences of
PERV-A or C SU, respectively, (2) a 2062 bp SalI–BamHI
fragment of pCIneo, and (3) a 748 bp BamHI–NotI of
pSK100. The pSK100 plasmid (a kind gift of Dr. John Young,
University of Wisconsin, Madison, WI) contains the coding
sequences for amino acids 96–323 of the rabbit immunoglobin
gamma heavy-chain gene (Genbank accession number P01870)
(Zingler and Young, 1996). The resulting plasmids, PERV-A
360 and PERV-C 360, contain residues 1–360 of PERV-A and
C envelope, respectively, fused in frame to the Ala-96 residue
of the rabbit IgG heavy chain coding sequences.
PERV-A 460 was constructed by amplification of a 1416 bp
fragment that contains the full-length PERV-A SU envelope
sequences using PCR with the following primers: pENV3-
SalKoz and PERVASU-reverse 2537 (5V GGACTAGTGGG-
CTC TCTTTTTGGCC3V). PERV-C 440 was constructed by
amplification of a 1322 bp fragment that contains the full-
length PERV-C SU envelope sequences using PCR with the
following primers: pENV3-SalKoz and PERVCSU-2443
(5VGGACTAGTTTGTGC ATGATTTCTGTAGTC 3V). The
constructs, PERV-A 460 and PERV-C 440 contain the full-
length SU fused to rabbit-IgG.
Plasmids PERV-A/C and PERV-C/A are chimeric envelopes
similar to pC1neoPERVA/C and pC1neoPERVC/A except that
they encode only the SU portion of ENVand are fused to rabbit
IgG. PERV-A/C was created by amplification of PERV-A/C
sequences from pC1neoPERV-A/C by PCR using primers
pENV3-SalCoz and PERVCSU-2443. Similarly, PERV-C/A
was created by amplification of PERV-C/A sequences from
pC1neoPERV-C/A by PCR using primers pENV3-SalCoz andPERVASU-reverse2537. The resulting PCR fragment was
ligated to pC1neo or pSK100 as described above.
All constructs were confirmed by restriction enzyme
analysis and sequence analysis.
Generation and characterization of PERV SU-rIgG fusion
proteins
To generate the PERV SU-rIgG fusion proteins, 8.5  105
293T cells were plated on 100 mm2 petri dishes 24 h prior to
CaPO4-mediated transient transfection using Profection Mam-
malian Transfection System-Calcium Phosphate(Promega,
Madison WI) with plasmids encoding PERV SU-rIgG fusion
proteins or a control plasmid encoding the SU-rIgG fusion
protein from the avian retrovirus ALSV-A (ALV-rIgG) (Zingler
and Young, 1996). Twenty-four hours post-transfection,
transfected cells were replenished with DMEM supplemented
with 50 Ag/ml of leupeptin and 5 Ag/ml of aprotinin. Cell
culture supernatant was collected 72 h post-transfection, and an
additional 50 Ag/ml of leupeptin and 5 Ag/ml of aprotinin were
added to the supernatant and stored at 80 -C for further use.
The concentration of SU-IgG fusion proteins was determined
by a rabbit-IgG specific enzyme-linked immunosorbent assay
(ELISA) by following manufacturer’s directions (Alpha Diag-
nostic International, San Antonio, TX). To further assess
protein expression and stability of PERV SU-rIg fusion
proteins, 1 ml of cell culture supernatant containing PERV
SU-rIgG fusion proteins was incubated with 20% protein A-
sepharose beads (Sigma, ST. Louis, MO.) for 1 h and protein
from immunopreciptates was assessed by SDS-PAGE and
Western blot analysis as described previously (Gemeniano et
al., 2003), with the following modification: the nitrocellulose
membrane was probed with monoclonal anti-goat IgG linked to
horseradish peroxidase. Bands were visualized using Chemi-
luminescence Reagent Plus (Perkin Elmer, Boston, MA) and
exposed to X-ray film.
Assessment for binding of envelope SU-rIgG and SU-HA fusion
proteins to target cells
Binding of PERV SU-rIgG was performed according to
methods previously described (Jones et al., 2002; Nath et al.,
2003). Briefly, 5  105 to 1  106 target cells were detached
using 0.5 M EDTA, resuspended in 0.2 ml of supernatant
containing various concentrations of PERV SU-rIgG as
indicated in the results, and incubated for 1 h on ice. The cells
were washed twice with cold PBS containing 2% FBS and then
incubated for 30 min on ice with anti-rabbit IgG antibody
conjugated to fluorescein isothiocyanate (FITC) (1:50 dilution)
(Jackson ImmunoResearch, West Grove, PA). The cells were
then washed twice with cold PBS containing 2% FBS and
resuspended in cold PBS containing 4% paraformaldehyde. For
experiments involving larger numbers of samples, cells were
fixed in 4% paraformaldehyde for 30 min on ice prior to
exposure to PERV SU-rIgG. To determine PERV SU-rIgG
binding, 10,000–15,000 live cell events were measured for
fluorescence on FACScan (BD PharMingen, San Diego, CA)
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Jose, CA). Data are represented as the Relative Mean
Fluorescence Intensity (MFI), whereby each MFI was norm-
alized to the highest mean fluorescence corresponding to a
value of one.
The binding of GALV-RBD to target cells was performed
similarly, with the exception of incubating target cells with the
HA-tagged envelope fragment at 37 -C shaking for 45 min,
followed by incubation with anti-HA antibody, HA.11 (Con-
vance, Princeton, NJ) at 37 -C for 45 min. The final incubation
was with goat anti-mouse IgG conjugated to FITC (Jackson
ImmunoResearch, West Grove, PA). Each incubation with
antibody was followed by washing cells with PBS supple-
mented with 1% FBS, as described previously (Farrell et al.,
2002).
Derivation of viral vector pseudotypes and infectivity assays
One million 293T cells were seeded in 10 cm2 tissue culture
dishes 24 h before transfections. Three expression vectors were
introduced into 293T cells by CaPO4-mediated transient
transfection using the Profectin Kit (Promega, Madison, WI)
(Soneoka et al., 1997; Ting et al., 1998): (1) pRT43.2Tnlsh-gal
(obtained from Tom Dull, Cell Genesys, Foster City, CA)
provided the Moloney murine leukemia virus (MoMuLV)-
based genome containing the packaging signal and the
h-galactosidase gene coding sequence, (2) a MuLV gag/pol
plasmid, and (3) pC1neoPERVA-1.38.2 or PERVC-3.7.2
envelope plasmids. The resulting pseudovirions are composed
of a MoMuLV-derived genome encoding h-galactosidase
within a MoMuLV core surrounded by PERV envelope
glycoproteins.
Infectivity was determined by histochemical determination
of h-galactosidase expression in target cells as previously
described (Wilson and Eiden, 1991). All infections were
performed in triplicate.
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